EG-009A

EG-009A is a selective glucocorticoid receptor modulator developed by Evergreen Therapeutics for the treatment of cytokine release syndrome (CRS) and moderate to severe pneumonia caused by COVID-19. The drug acts as an anti-inflammatory agent, selectively regulating key glucocorticoid receptor target genes such as ENaC, FKBP5, and GILZ. This targeted modulation provides potent anti-inflammatory effects while aiming to reduce typical steroid-related side effects like secondary infections or femoral head necrosis, making it suitable for long-term use. EG-009A is administered intramuscularly and has been evaluated in Phase II clinical trials for its efficacy in reducing pulmonary failure and improving survival rates among hospitalized COVID-19 patients with severe symptoms[1][5][7].